Rhumbline Advisers Bio Rad Laboratories, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Bio Rad Laboratories, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 54,236 shares of BIO stock, worth $17.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

54,236

Previous 34,863 55.57%

Holding current value

$17.4 Million

Previous $9.52 Million 90.59%

% of portfolio

0.02%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$263.97 - $344.64 $5.11 Million - $6.68 Million	19,373 Added 55.57%	54,236 $18.1 Million
Q2 2024 Aug 01, 2024	SELL	$268.26 - $339.48 $659,114 - $834,102	-2,457 Reduced 6.58%	34,863 $9.52 Million
Q1 2024 May 09, 2024	SELL	$304.11 - $351.99 $54,739 - $63,358	-180 Reduced 0.48%	37,320 $12.9 Million
Q4 2023 Feb 08, 2024	BUY	$269.37 - $365.04 $218,189 - $295,682	810 Added 2.21%	37,500 $12.1 Million
Q3 2023 Nov 09, 2023	BUY	$350.25 - $422.63 $31,522 - $38,036	90 Added 0.25%	36,690 $13.2 Million
Q2 2023 Aug 08, 2023	SELL	$359.49 - $486.4 $305,566 - $413,440	-850 Reduced 2.27%	36,600 $13.9 Million
Q1 2023 May 11, 2023	BUY	$418.69 - $503.0 $391,893 - $470,808	936 Added 2.56%	37,450 $17.9 Million
Q4 2022 Feb 14, 2023	BUY	$351.71 - $456.01 $562,384 - $729,159	1,599 Added 4.58%	36,514 $15.4 Million
Q3 2022 Nov 10, 2022	BUY	$412.59 - $563.26 $232,288 - $317,115	563 Added 1.64%	34,915 $14.6 Million
Q2 2022 Aug 11, 2022	BUY	$463.67 - $597.16 $2.2 Million - $2.83 Million	4,740 Added 16.01%	34,352 $17 Million
Q1 2022 May 12, 2022	SELL	$524.57 - $735.42 $12.4 Million - $17.3 Million	-23,582 Reduced 44.33%	29,612 $16.7 Million
Q4 2021 Feb 10, 2022	BUY	$708.84 - $794.68 $3.4 Million - $3.81 Million	4,796 Added 9.91%	53,194 $40.2 Million
Q3 2021 Nov 12, 2021	SELL	$657.71 - $825.77 $14,469 - $18,166	-22 Reduced 0.05%	48,398 $36.1 Million
Q2 2021 Aug 05, 2021	BUY	$576.64 - $649.04 $1.43 Million - $1.61 Million	2,486 Added 5.41%	48,420 $31.2 Million
Q1 2021 May 06, 2021	SELL	$547.01 - $662.35 $640,548 - $775,611	-1,171 Reduced 2.49%	45,934 $26.2 Million
Q4 2020 Feb 10, 2021	SELL	$510.68 - $643.45 $1.81 Million - $2.28 Million	-3,536 Reduced 6.98%	47,105 $27.5 Million
Q3 2020 Nov 12, 2020	SELL	$454.43 - $535.6 $2.02 Million - $2.38 Million	-4,444 Reduced 8.07%	50,641 $26.1 Million
Q2 2020 Aug 13, 2020	SELL	$334.87 - $493.06 $620,848 - $914,133	-1,854 Reduced 3.26%	55,085 $24.9 Million
Q1 2020 May 06, 2020	BUY	$320.01 - $409.07 $1.46 Million - $1.86 Million	4,557 Added 8.7%	56,939 $20 Million
Q4 2019 Feb 05, 2020	SELL	$319.73 - $374.2 $340,512 - $398,523	-1,065 Reduced 1.99%	52,382 $19.4 Million
Q3 2019 Oct 23, 2019	BUY	$304.55 - $345.24 $583,213 - $661,134	1,915 Added 3.72%	53,447 $17.8 Million
Q2 2019 Aug 14, 2019	SELL	$286.93 - $312.59 $61,403 - $66,894	-214 Reduced 0.41%	51,532 $16.1 Million
Q1 2019 May 01, 2019	SELL	$224.3 - $317.41 $766,208 - $1.08 Million	-3,416 Reduced 6.19%	51,746 $15.8 Million
Q4 2018 Jan 31, 2019	BUY	$220.1 - $309.0 $3.48 Million - $4.88 Million	15,793 Added 40.12%	55,162 $12.8 Million
Q3 2018 Nov 07, 2018	SELL	$289.28 - $326.15 $472,394 - $532,602	-1,633 Reduced 3.98%	39,369 $12.3 Million
Q2 2018 Aug 06, 2018	SELL	$244.1 - $303.88 $805,530 - $1 Million	-3,300 Reduced 7.45%	41,002 $11.8 Million
Q1 2018 May 02, 2018	SELL	$233.97 - $274.11 $545,852 - $639,498	-2,333 Reduced 5.0%	44,302 $11.1 Million
Q4 2017 Feb 09, 2018	BUY	$216.94 - $271.3 $446,028 - $557,792	2,056 Added 4.61%	46,635 $11.1 Million
Q3 2017 Nov 06, 2017	BUY	$212.27 - $242.28 $9.46 Million - $10.8 Million	44,579	44,579 $9.91 Million

Others Institutions Holding BIO

# of Institutions

457

Shares Held

18.3M

Call Options Held

19.5K

Put Options Held

13.9K

View Full List

About BIO-RAD LABORATORIES, INC.

Ticker BIO
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 24,633,900
Market Cap $7.89B
Description
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, an...

More about BIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Bio Rad Laboratories, Inc. Transaction History